<SEC-DOCUMENT>0001437749-22-022919.txt : 20220922
<SEC-HEADER>0001437749-22-022919.hdr.sgml : 20220922
<ACCEPTANCE-DATETIME>20220922161613
ACCESSION NUMBER:		0001437749-22-022919
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20220922
DATE AS OF CHANGE:		20220922

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NovaBay Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001389545
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				680454536
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33678
		FILM NUMBER:		221259406

	BUSINESS ADDRESS:	
		STREET 1:		2000 POWELL STREET, SUITE 1150
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		(510) 899-8800

	MAIL ADDRESS:	
		STREET 1:		2000 POWELL STREET, SUITE 1150
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>nby20220922_defa14a.htm
<DESCRIPTION>FORM DEFA14A
<TEXT>
<html><head>
	<title>nby20220922_defa14a.htm</title>

	<!-- Generated by ThunderDome Portal - 9/22/2022 7:18:54 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>UNITED STATES</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Washington, D.C. 20549</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>SCHEDULE 14A INFORMATION</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Proxy Statement Pursuant to Section 14(a) of</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>the Securities Exchange Act of 1934 </b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>(Amendment No.</b>&nbsp;<b> </b>&nbsp;<b> )</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Filed by the Registrant &#9746;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Filed by a Party other than the Registrant&nbsp;&#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Check the appropriate box:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Preliminary Proxy Statement</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Definitive Proxy Statement</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Definitive Additional Materials</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9746;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Soliciting Material Pursuant to &#167;&nbsp;240.14a-12</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>NOVABAY PHARMACEUTICALS, INC. </b></p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">(Name of Registrant as Specified in Its Charter)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Payment of Filing Fee (Check the appropriate box):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9746;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">No fee required</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Fee paid previously with preliminary materials</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div><img alt="nb01.jpg" src="nb01.jpg"></div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NovaBay Pharmaceuticals CEO Issues Letter to Stockholders</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>EMERYVILLE, Calif. (September 22, 2022)</b> &#8211; <u>NovaBay</u><u>&#174;</u><u> Pharmaceuticals, Inc</u>. (NYSE American: NBY) announces that Chief Executive Officer Justin Hall has issued the following Letter to Stockholders:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">To My Fellow Stockholders:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Over the past year, we have successfully transformed NovaBay from a single product company into a larger organization with three brands in three distinct market segments. We are a stronger company with established brands in the large and growing eyecare, skincare and wound care markets. Our Avenova&#174;, DERMAdoctor&#174; and PhaseOne&#174; products all have loyal customer bases, resulting in recurring revenue and a solid foundation for growth as we execute an aggressive commercial strategy. We differentiate our products from our competitors by being <i>scientifically developed and clinically proven</i>. Our high-quality products are all manufactured in the United States.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As our stockholders know, on September 9, 2022, NovaBay entered into two financing transactions. I would like to acknowledge the concerns that many stockholders have shared with me about our current need to raise additional capital and effect a reverse stock split. Although we started the year with no intention of doing either of those, our situation has changed. We need additional capital to fully implement our growth strategies, such as launching new products on the QVC&#174; network and expanding into the European and Chinese markets. In connection with the financing transactions, we are required to seek stockholder approval of a reverse stock split. We expect that the reverse stock split will increase the market price of our common stock so that NovaBay will be able to satisfy the continued listing requirements of the NYSE American for the foreseeable future. We also believe that a reverse stock split may improve the marketability and liquidity of our common stock and appeal to a broader range of investors and generate greater investor interest. Further, due to the number of shares of common stock underlying the securities issued, or to be issued, in connection with the financing transactions, the NYSE American rules require that we seek stockholder approval prior to the issuance of those underlying shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We currently anticipate holding a special meeting of stockholders on November 10, 2022 to seek stockholder approvals on the proposals outlined above.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Despite the current need for financing, there are many reasons to be optimistic about our future. More people are using Avenova today than ever before, with more than 600 units selling on Amazon each day, representing an 18% year-over-year increase in unit sales. To support further growth, we are expanding the customer demographic for Avenova by entering into the eyelash extension market. A growing number of women are turning to eyelash extensions to enhance their appearance, driving a market that&#8217;s projected to reach $2.4 billion by 2031. Yet lash extensions can attract oil, dust, dirt and debris that may shorten their lifespan, cause irritation and increase the likelihood of eye infections. Our antimicrobial formulation is clinically proven to kill infection-causing bacteria and remove the irritants on lids and lashes, and, as an added benefit, Avenova does not damage the adhesive that holds extensions in place extending lash life.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We are capitalizing on the trend for beauty products to be increasingly purchased online by broadening availability of select DERMAdoctor products through two popular U.S. online retailers, <u>Target.com</u> and <u>Urbanoutfitters.com</u>. Brand influencers play an important role in the beauty industry and we continue to build on the enviable position of our Chief Product Officer and board-certified dermatologist Dr. Audrey Kunin as a skincare thought-leader through interviews with popular online consumer publications and guest appearances on the QVC network.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Expanding marketing activities to certain overseas geographies is also a key priority to driving sales growth. To that end, we recently engaged a new partner in China to manage DERMAdoctor&#8217;s flagship store on Tmall.com, which is the leading business-to-consumer online retailer in China. Brand influencers and social media platforms like TikTok are particularly effective ways to attract new customers in China, and our marketing partner brings an extensive network of bloggers and influencers, as well as strong social media brand-building capabilities. We anticipate DERMAdoctor&#8217;s TikTok store in China to go live in November of this year. We are also in the process of onboarding a distribution partner in the European Union, a previously untapped market for us.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Lastly, we launched seven new products since the beginning of 2022. This includes both new Avenova and DERMAdoctor products, keeping us highly relevant in industries that are characterized by rapid change. All our new offerings reinforce our corporate positioning of formulating and selling proprietary OTC products that are effective, scientifically developed, clinically proven and gentle, while addressing common yet underserved conditions. Importantly, all of our new product creations and launch activities are efficiently managed under a low-cost model.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Looking forward, we still anticipate a strong end to the year. A large seasonal order from Costco for DERMAdoctor&#8217;s top-selling product, Kakadu C, will increase revenue in the third and fourth quarters. We also generally expect a spike in DERMAdoctor sales during the fall, which is the seasonally strongest period for skincare products. These developments underscore our confidence for continued growth.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As we gain traction from our initiatives and favorable industry trends, we expect continued growth through 2022 and into 2023. On behalf of my NovaBay colleagues and our Board of Directors, I appreciate your continued support of our path to profitability.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Sincerely,</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div><img alt="nb02.jpg" src="nb02.jpg"></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Justin Hall, Esq.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Chief Executive Officer and General Counsel</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">September 22, 2022</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>About NovaBay Pharmaceuticals, Inc.: </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">NovaBay Pharmaceuticals, Inc. is a pharmaceutical company that develops and sells scientifically created and clinically proven eyecare and skincare products. Avenova&#174; is the most prescribed antimicrobial lid and lash spray and DERMAdoctor&#174; is a premium skincare brand offering more than 30 dermatologist-developed skincare products sold through traditional domestic retailers, digital beauty channels and international distributors.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NovaBay Pharmaceuticals Forward-Looking Statements</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This press release contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements that are based upon management&#8217;s current expectations, assumptions, estimates, projections and beliefs. The use of words such as, but not limited to, &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; or &#8220;would&#8221; and similar words or expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding our business strategies, ability to complete certain financing transactions, current and future product offerings, marketing efforts, and any future revenue that may result from selling such products, as well as generally the Company&#8217;s expected future financial results (and ability to continue as a going concern) and the impact of a reverse stock split. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Other risks relating to NovaBay&#8217;s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay&#8217;s latest Form 10-Q/K filings with the Securities and Exchange Commission (the &#8220;Commission&#8221;), especially under the heading &#8220;Risk Factors,&#8221; and in the Preliminary Proxy Statement filed by NovaBay with the Commission, especially under the heading &#8220;Proposal Two: The Reverse Stock Split Proposal &#8212; Risks Relating to the Reverse Stock Split.&#8221; The forward-looking statements in this press release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Additional Information</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As referenced above, certain stockholder matters will need to be voted upon (the &#8220;Stockholder Matters&#8221;) and the Company filed a preliminary proxy statement with the Commission on September 20, 2022, and intends to subsequently mail or otherwise make available a definitive proxy statement relating to the Stockholder Matters. This press release does not contain all the information that should be considered concerning the Stockholder Matters, and is not intended to form the basis of any voting decision, investment decision or any other decision in respect of the Stockholder Matters. The Company&#8217;s stockholders and other interested persons are advised to read the preliminary proxy statement and the amendments thereto and the definitive proxy statement and other documents filed in connection with the Stockholder Matters, as these materials will contain important information about these matters, as well as the Company and the related financing transactions. When available, the definitive proxy statement and other relevant materials will be sent or given to stockholders of the Company as of a record date to be established for voting on the Stockholder Matters. Stockholders will also be able to obtain copies of the preliminary proxy statement, the definitive proxy statement and other documents filed with the Commission, without charge, once available, at the Commission&#8217;s website at www.sec.gov, or by directing a request to: NovaBay Pharmaceuticals, Inc., 2000 Powell Street, Suite 1150, Emeryville, CA 94608, attention: Corporate Secretary.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Participants in the Solicitation</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company and its directors and executive officers may be deemed participants in the solicitation of proxies from the Company&#8217;s stockholders with respect to the Stockholder Matters. A list of the names of those directors and executive officers and a description of their interests in the Company is contained in the Company&#8217;s filings with the Commission, including in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the Commission and is available free of charge at the Commission&#8217;s website at www.sec.gov, or by directing a request to: NovaBay Pharmaceuticals, Inc., 2000 Powell Street, Suite 1150, Emeryville, CA 94608, attention: Corporate Secretary. Additional information regarding the interests of such participants is contained in the preliminary proxy statement and will be contained in the definitive proxy statement for the Stockholder Matters when available. In addition, we have engaged Alliance Advisors, LLC, to assist in the solicitation of proxies and provide related advice and informational support.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><u>Socialize and Stay Informed on NovaBay</u></b><u>&#8217;</u><b><u>s Progress </u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Like us on <u>Facebook</u></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Follow us on <u>Twitter</u></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Connect with NovaBay on <u>LinkedIn</u></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Visit NovaBay&#8217;s <u>Website</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><u>Avenova Purchasing Information </u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For NovaBay Avenova purchasing information:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Please call 800-890-0329 or email sales@avenova.com</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Avenova.com</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><u>DERMAdoctor Purchasing Information </u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For DERMAdoctor purchasing information:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Please call 877-337-6237 or email service@dermadoctor.com</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>DERMAdoctor.com</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><u>NovaBay Contact </u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Justin Hall</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Chief Executive Officer and General Counsel</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">510-899-8800</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>jhall@novabay.com</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><u>Investor Contact </u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">LHA Investor Relations</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Jody Cain</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">310-691-7100<br>
<u>jcain@lhai.com</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"># # #</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>nb01.jpg
<TEXT>
begin 644 nb01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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MEXJ7<ES:7 1U\X@NC@;3T &" *RYO!!DEO+L3?Z7+J8O(SYK^6$#*<%,[2<
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(@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>nb02.jpg
<TEXT>
begin 644 nb02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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M4N*,4 )12XHQ0 E%+BC% "44N*,4 )12XHQ0 E%+BC% "44N*,4 )12XHQ0
'"BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
